Search results
Results from the WOW.Com Content Network
In both trials, participants were randomly assigned to either receive eflapegrastim or pegfilgrastim under the skin (subcutaneously) approximately 24 hours after anticancer treatment. [4] Participants in both groups were evaluated and compared for the duration of severe neutropenia (a condition with lower-than-normal levels of neutrophils in ...
Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. [23] Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). [24] [23]
Efbemalenograstim alfa can cause fatal splenic rupture, acute respiratory distress syndrome, serious allergic reactions including anaphylaxis, sickle cell crises in patients with sickle cell disorders, glomerulonephritis, thrombocytopenia, capillary leak syndrome, and myelodysplastic syndrome and acute myeloid leukemia in people with breast and lung cancer.
Biotech giant Amgen announced in a press release Saturday that its PAVES phase 3 trial to evaluate colorectal cancer patients taking the white blood cell-boosting drug Neulasta met its primary ...
The AOL.com video experience serves up the best video content from AOL and around the web, curating informative and entertaining snackable videos.
"Had just found out my chemo treatment plan a few minutes before the therapy dogs made their rounds and Gracie just happened to also be my favorite breed, Golden Retriever! Made all my emotions ...
G-CSF when given early after exposure to radiation may improve white blood cell counts, and is stockpiled for use in radiation incidents. [24] [25] Mesoblast planned in 2004 to use G-CSF to treat heart degeneration by injecting it into the blood-stream, plus SDF (stromal cell-derived factor) directly to the heart. [26]
Shortly after it was introduced, analyses of whether filgrastim is a cost-effective way of preventing febrile neutropenia depended upon the clinical situation and the financial model used to pay for treatment. [36] The longer-acting pegfilgrastim may in some cases be more cost-effective. [37]